文献速递临床试验与 GCP真实世界研究与卫生经济

非手术石膏固定与手术复位治疗儿童严重移位桡骨远端骨折(CRAFFT研究):多中心随机对照非劣效试验及经济学评价

Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation.
PubMed 文献 · Lancet · 2026-04-08

CRAFFT多中心随机非劣效试验纳入750例4-10岁严重移位桡骨远端骨折患儿,比较非手术石膏固定与手术复位。非手术石膏固定人均费用降低1665英镑,具有成本效果。

要点

  • 手术复位早期并发症更多,包括压伤、伤口感染、瘢痕和神经刺激

核心结论

  • CRAFFT试验未在3个月时以保守界值证明非手术石膏固定的非劣效性,但手术复位优势微小、低于家庭认为有意义的阈值,且未持续至早期恢复后。
  • 手术复位费用更高、早期操作并发症更多,仅轻微改善外观,支持对多数患儿考虑石膏优先策略。

研究设计与样本

  • 实用型多中心随机对照非劣效试验,纳入英国49家医院4-10岁严重移位桡骨远端骨折患儿。
  • 750例参与者随机分配至非手术石膏固定组(375例)或手术复位组(375例),采用最小化算法随机分组并按中心、年龄组、骨折部位和移位严重程度分层。
  • 同时进行基于英国NHS和个人社会服务视角的12个月成本效果评价。

主要发现

  • 8周内多数并发症发生于手术复位组,包括压伤(n=2)、伤口感染(n=6)、瘢痕(n=5)和神经刺激(n=1)。
  • 12个月随访期间再骨折13例(非手术石膏固定后9例,手术复位后4例)。

临床怎么用

  • 对多数严重移位桡骨远端骨折患儿可考虑石膏优先策略,因手术复位功能优势微小且未持续。
  • 手术复位与更高费用和早期操作并发症相关,决策时应结合家庭对功能差异的意愿。

局限性

  • 参与者和家长无法对治疗分配设盲。
  • 主要结局数据仅从640例(85%)参与者中收集。
  • 3年延长随访仍在进行中,长期结果尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severely displaced distal radial fractures are among the most common and controversial injuries in children. Despite observational evidence of reliable remodelling with growth in younger children, their alarming radiographic appearance-particularly when completely displaced (off-ended)-has driven routine surgical reduction and fixation. The Children's Radius Acute Fracture Fixation Trial (CRAFFT) aimed to evaluate the clinical and cost-effectiveness of surgical reduction compared with non-surgical casting. METHODS: This pragmatic, multicentre, randomised, non-inferiority trial included participants (aged 4-10 years) with a severely displaced distal radial fracture from 49 hospitals in the UK. Recruiting centres were secondary or tertiary care hospitals providing acute paediatric trauma care. Participants were randomly assigned to either non-surgical casting or surgical reduction, using a minimisation algorithm with a random element and stratification factors were centre, age group, fracture location, and displacement severity. Participants and their parents and carers could not be masked to treatment. Surgical reduction was performed under general anaesthesia or conscious sedation, to restore anatomical alignment, with fixation permitted at the discretion of the surgeon. Non-surgical care involved immobilisation of the fracture in a plaster cast without general anaesthesia or sedation, and without purposeful manipulation of the fracture position. Immobilisation of the fracture beyond 6 weeks post-randomisation was not recommended. The primary outcome was upper limb function at 3 months, measured using the Patient Report Outcomes Measurement System (PROMIS) Upper Extremity Score for Children in the intention-to-treat population, which included all participants in the groups to which they were randomly assigned, irrespective of treatment received. The non-inferiority margin was conservatively set at -2·5 points for the main trial population. A prespecified subgroup analysis was powered to assess whether non-surgical casting could exclude a larger more clinically relevant margin of -5 points among children with completely off-ended fractures. Complications and serious adverse events were summarised in a safety (as-treated) population defined by treatment received. A within-trial economic evaluation was undertaken from the perspective of the UK National Health Service (NHS) and Personal Social Services over a 12-month time period. The trial was registered with the ISRCTN registry, ISRCTN10931294, recruitment is complete and extended follow-up to 3-years post-randomisation is ongoing. FINDINGS: Between Aug 11, 2020, and May 30, 2024, 1227 children were screened for eligibility across 49 UK hospitals. 477 children were excluded (54 met exclusion criteria and 423 did not enter the study, the majority for lack of clinical or parental equipoise). 750 participants were randomly assigned, 375 to the non-surgical casting group and 375 to the surgical reduction group. 456 (61%) participants were male, 294 (39%) were female, and the median age of participants was 7·9 years (IQR 6·5-9·5). 329 (44%) of the 750 participants had completely off-ended fractures. Primary outcome data were collected from 640 (85%) participants. At 3 months post-randomisation, the mean PROMIS Upper Extremity score was 44·9 (SD 8·7) in the non-surgical casting group and 46·6 (8·8) in the surgical reduction group (adjusted mean difference -1·64 [95% CI -2·84 to -0·44]), with the confidence interval favouring surgical reduction but extending beyond the prespecified non-inferiority margin of -2·5 points. In children with completely off-ended fractures, findings were consistent with non-inferiority against the wider, prespecified margin for this group. Most complications within 8 weeks occurred in the surgical reduction group, including pressure damage (n=2), wound infections (n=6), scarring (n=5), and nerve irritation (n=1). During the 12-months of follow-up, refracture occurred in 13 participants (nine after non-surgical casting and four after surgical reduction). From an NHS and Personal Social Services perspective, non-surgical casting was associated with a significant reduction in mean cost per patient of £1665 (95% CI 1487 to 1843) and a marginal incremental reduction in quality-adjusted life-years (QALYs; -0·023 [95% CI -0·037 to -0·009]). The probability of non-surgical casting being cost-effective at the £20 000 and £30 000 per QALY threshold was 100%, indicating that the small short-term functional advantage of surgical reduction was not cost-effective. INTERPRETATION: The CRAFFT trial did not demonstrate non-inferiority of non-surgical casting at 3 months against a conservative margin; however, the observed difference in favour of surgical reduction was small, below thresholds that families considered meaningful, and did not persist beyond early recovery. Surgical reduction was associated with higher costs, early procedural complications, and only a modest improvement in cosmetic appearance, supporting consideration of a cast-first strategy for most children. FUNDING: National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (17/22/02) and the NIHR Oxford Biomedical Research Centre.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Perry DC, Zimmermann A, Achten J, et al. Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation. Lancet. 2026. PMID: 41965242. doi:10.1016/S0140-6736(26)00409-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。